Targeting tumor angiogenesis

Stefania Staibano, Paolo Antonio Ascierto

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Four decades after the seminal work of Judah Folkman, in 1971, cancer therapies based on the suppression of neo-angiogenesis (Folkman, N Engl J Med 285:1182-1186, 1971) are becoming a reality (Verheul et al., Clin Cancer Res 14(11):3589-3597, 2008). The shift toward the up-regulation of pro-angiogenic factors secretion from both tumor and stroma, results from the interplay between endothelial cell activation, proliferation, extracellular matrix degradation, migration, canalization. It leads to the generation of a chaotic vascular vessels network in prostate cancer tissue (Ahmed and Bicknell, Method Mol Biol 467:3-24, 2009), which can be detected also by modern imaging techniques based on magnetic resonance, ultrasound, and nuclear imaging through targeting of key angiogenic factors (Russo et al., BJU Int 110(11 Pt C):E794-E808, 2012). This hopefully will lead to further improvements in prostate cancer diagnosis and staging. Preclinical evidence indicates that angiogenesis inhibitors can improve the efficacy of conventional cytotoxic agents mainly by normalizing tumor blood flow, thus improving drug delivery. Although significant biological activity of most vascular growth factors-interfering agents is demonstrated in preclinical models, single-agent activity is almost universally poor (Aragon-Ching et al., J Oncol 2010:361836, 2010). Due to the redundancy within the signalling pathways that promote angiogenesis, combining anti-angiogenic agents with different mechanisms of action seems likely to significatively potentiate their therapeutic efficacy (Corcoran and Gleave 2012; Ellis and Hicklin, Nat Rev Cancer 8:579-591, 2008; Verheul et al., Cancer Chemother Pharmacol 60:29-39, 2007).

Original languageEnglish
Title of host publicationProstate Cancer: Shifting from Morphology to Biology
PublisherSpringer Netherlands
Pages221-231
Number of pages11
ISBN (Print)9789400771499, 9400771487, 9789400771482
DOIs
Publication statusPublished - Jul 1 2013

Fingerprint

Neoplasms
Angiogenesis Inducing Agents
Prostatic Neoplasms
Angiogenesis Inhibitors
Neoplasm Staging
Cytotoxins
Extracellular Matrix
Blood Vessels
Ultrasonography
Intercellular Signaling Peptides and Proteins
Up-Regulation
Magnetic Resonance Spectroscopy
Endothelial Cells
Cell Proliferation
Therapeutics
Pharmaceutical Preparations
vascular factor

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Staibano, S., & Ascierto, P. A. (2013). Targeting tumor angiogenesis. In Prostate Cancer: Shifting from Morphology to Biology (pp. 221-231). Springer Netherlands. https://doi.org/10.1007/978-94-007-7149-9_14

Targeting tumor angiogenesis. / Staibano, Stefania; Ascierto, Paolo Antonio.

Prostate Cancer: Shifting from Morphology to Biology. Springer Netherlands, 2013. p. 221-231.

Research output: Chapter in Book/Report/Conference proceedingChapter

Staibano, S & Ascierto, PA 2013, Targeting tumor angiogenesis. in Prostate Cancer: Shifting from Morphology to Biology. Springer Netherlands, pp. 221-231. https://doi.org/10.1007/978-94-007-7149-9_14
Staibano S, Ascierto PA. Targeting tumor angiogenesis. In Prostate Cancer: Shifting from Morphology to Biology. Springer Netherlands. 2013. p. 221-231 https://doi.org/10.1007/978-94-007-7149-9_14
Staibano, Stefania ; Ascierto, Paolo Antonio. / Targeting tumor angiogenesis. Prostate Cancer: Shifting from Morphology to Biology. Springer Netherlands, 2013. pp. 221-231
@inbook{efad7fbd5a7542f993accceabde2043d,
title = "Targeting tumor angiogenesis",
abstract = "Four decades after the seminal work of Judah Folkman, in 1971, cancer therapies based on the suppression of neo-angiogenesis (Folkman, N Engl J Med 285:1182-1186, 1971) are becoming a reality (Verheul et al., Clin Cancer Res 14(11):3589-3597, 2008). The shift toward the up-regulation of pro-angiogenic factors secretion from both tumor and stroma, results from the interplay between endothelial cell activation, proliferation, extracellular matrix degradation, migration, canalization. It leads to the generation of a chaotic vascular vessels network in prostate cancer tissue (Ahmed and Bicknell, Method Mol Biol 467:3-24, 2009), which can be detected also by modern imaging techniques based on magnetic resonance, ultrasound, and nuclear imaging through targeting of key angiogenic factors (Russo et al., BJU Int 110(11 Pt C):E794-E808, 2012). This hopefully will lead to further improvements in prostate cancer diagnosis and staging. Preclinical evidence indicates that angiogenesis inhibitors can improve the efficacy of conventional cytotoxic agents mainly by normalizing tumor blood flow, thus improving drug delivery. Although significant biological activity of most vascular growth factors-interfering agents is demonstrated in preclinical models, single-agent activity is almost universally poor (Aragon-Ching et al., J Oncol 2010:361836, 2010). Due to the redundancy within the signalling pathways that promote angiogenesis, combining anti-angiogenic agents with different mechanisms of action seems likely to significatively potentiate their therapeutic efficacy (Corcoran and Gleave 2012; Ellis and Hicklin, Nat Rev Cancer 8:579-591, 2008; Verheul et al., Cancer Chemother Pharmacol 60:29-39, 2007).",
author = "Stefania Staibano and Ascierto, {Paolo Antonio}",
year = "2013",
month = "7",
day = "1",
doi = "10.1007/978-94-007-7149-9_14",
language = "English",
isbn = "9789400771499",
pages = "221--231",
booktitle = "Prostate Cancer: Shifting from Morphology to Biology",
publisher = "Springer Netherlands",

}

TY - CHAP

T1 - Targeting tumor angiogenesis

AU - Staibano, Stefania

AU - Ascierto, Paolo Antonio

PY - 2013/7/1

Y1 - 2013/7/1

N2 - Four decades after the seminal work of Judah Folkman, in 1971, cancer therapies based on the suppression of neo-angiogenesis (Folkman, N Engl J Med 285:1182-1186, 1971) are becoming a reality (Verheul et al., Clin Cancer Res 14(11):3589-3597, 2008). The shift toward the up-regulation of pro-angiogenic factors secretion from both tumor and stroma, results from the interplay between endothelial cell activation, proliferation, extracellular matrix degradation, migration, canalization. It leads to the generation of a chaotic vascular vessels network in prostate cancer tissue (Ahmed and Bicknell, Method Mol Biol 467:3-24, 2009), which can be detected also by modern imaging techniques based on magnetic resonance, ultrasound, and nuclear imaging through targeting of key angiogenic factors (Russo et al., BJU Int 110(11 Pt C):E794-E808, 2012). This hopefully will lead to further improvements in prostate cancer diagnosis and staging. Preclinical evidence indicates that angiogenesis inhibitors can improve the efficacy of conventional cytotoxic agents mainly by normalizing tumor blood flow, thus improving drug delivery. Although significant biological activity of most vascular growth factors-interfering agents is demonstrated in preclinical models, single-agent activity is almost universally poor (Aragon-Ching et al., J Oncol 2010:361836, 2010). Due to the redundancy within the signalling pathways that promote angiogenesis, combining anti-angiogenic agents with different mechanisms of action seems likely to significatively potentiate their therapeutic efficacy (Corcoran and Gleave 2012; Ellis and Hicklin, Nat Rev Cancer 8:579-591, 2008; Verheul et al., Cancer Chemother Pharmacol 60:29-39, 2007).

AB - Four decades after the seminal work of Judah Folkman, in 1971, cancer therapies based on the suppression of neo-angiogenesis (Folkman, N Engl J Med 285:1182-1186, 1971) are becoming a reality (Verheul et al., Clin Cancer Res 14(11):3589-3597, 2008). The shift toward the up-regulation of pro-angiogenic factors secretion from both tumor and stroma, results from the interplay between endothelial cell activation, proliferation, extracellular matrix degradation, migration, canalization. It leads to the generation of a chaotic vascular vessels network in prostate cancer tissue (Ahmed and Bicknell, Method Mol Biol 467:3-24, 2009), which can be detected also by modern imaging techniques based on magnetic resonance, ultrasound, and nuclear imaging through targeting of key angiogenic factors (Russo et al., BJU Int 110(11 Pt C):E794-E808, 2012). This hopefully will lead to further improvements in prostate cancer diagnosis and staging. Preclinical evidence indicates that angiogenesis inhibitors can improve the efficacy of conventional cytotoxic agents mainly by normalizing tumor blood flow, thus improving drug delivery. Although significant biological activity of most vascular growth factors-interfering agents is demonstrated in preclinical models, single-agent activity is almost universally poor (Aragon-Ching et al., J Oncol 2010:361836, 2010). Due to the redundancy within the signalling pathways that promote angiogenesis, combining anti-angiogenic agents with different mechanisms of action seems likely to significatively potentiate their therapeutic efficacy (Corcoran and Gleave 2012; Ellis and Hicklin, Nat Rev Cancer 8:579-591, 2008; Verheul et al., Cancer Chemother Pharmacol 60:29-39, 2007).

UR - http://www.scopus.com/inward/record.url?scp=84929532020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929532020&partnerID=8YFLogxK

U2 - 10.1007/978-94-007-7149-9_14

DO - 10.1007/978-94-007-7149-9_14

M3 - Chapter

SN - 9789400771499

SN - 9400771487

SN - 9789400771482

SP - 221

EP - 231

BT - Prostate Cancer: Shifting from Morphology to Biology

PB - Springer Netherlands

ER -